Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

After last week’s essay about this disease condition, it has become necessary to help readers understand the peculiar nature of the organ.

Germline and Somatic Testing Guidelines and Challenges Guidelines now recommend germline panel testing for all patients diagnosed with pancreatic cancer (excluding neuroendocrine tumors), regardless ...

Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms ...

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

She has worked with diverse community partners to develop and conduct culturally relevant interventions to reduce cancer risk and address public health concerns brought forth by the community. Dr.

Table 1. Clinical characteristics of reported cases of rectal-NETs. From the lungs to the gastrointestinal tract and the pancreas, neuroendocrine tumors can emerge in almost any body part, each site ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

The FDA has ap­proved Ex­elix­is’ can­cer drug Cabome­tyx to treat ad­vanced neu­roen­docrine tu­mors in­side and out­side of the pan­creas, mark­ing two new in­di­ca­tions for ...